Kinetics of Torque Teno virus in heart transplant patients

• Published in: Human immunology 2023-12, Vol.84 (12), p.110720-110720, Article 110720
• Main Authors: Berg, Randi, Clemmensen, Tor S., Petersen, Mikkel S., Mogensen, Lone J.H., Christiansen, Mette, Rolid, Katrine, Nytrøen, Kari, Møller, Bjarne K., Gullestad, Lars, Eiskjær, Hans, Koefoed-Nielsen, Pernille
• Format: Article
• Language: English
• Subjects: Heart; Monitoring; Rejection; Torque Teno Virus; Transplantation
• ISSN: 0198-8859; 1879-1166
• DOI: 10.1016/j.humimm.2023.110720

End-stage heart failure often requires heart transplantation as a life-prolonging treatment. Immunosuppressive therapy is necessary to avoid rejection, but is associated with serious adverse effects. New approaches are needed to monitor immune function in heart transplant patients. We here report the kinetics of Torque Teno Virus (TTV) after transplantation in a large cohort of heart transplant patients and examine its possible role in predicting rejection. We included 106 patients from Aarhus University Hospital and Oslo University Hospital. Patients were followed for 3 years with clinical assessments, biopsies, TTV measurements, and flowcytometric phenotyping. We observed TTV levels reaching a maximum 3 months after transplantation for all 106 patients, after which levels gradually declined. 38 patients (38 %) had biopsy-proven rejection within the first year. We did not find evidence of an association between TTV and serum trough levels, events of rejection, nor flow cytometric immunophenotype. We report data on a large cohort of heart transplant patients and contribute to the understanding of how TTV behaves in transplant patients. Despite not finding an association with rejection, our results provide important insights into the kinetics of TTV levels after transplantation, which may be useful in future studies of immune function in heart transplant patients.